CMS Expands Off-Label Prescription Drug Use for Cancer Treatment

Baker Donelson
Contact
LinkedIn
Facebook
X
Send
Embed

Ober|Kaler's Craig Holden and Mark Stanley discuss CMS's recently issued interim final rule that expands Medicare coverage for certain off-label uses of drugs in anticancer chemotherapy regimens.

Please see full publication below for more information.

View PDF
Download PDF [31KB]
Email
Report

LOADING PDF: If there are any problems, click here to download the file.
Send Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Baker Donelson

Written by:

Baker Donelson
Baker Donelson
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Baker Donelson on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide